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and Vinorelbine-Containing Conditioning Regimen
for Autologous Hematopoietic Cell Transplantation
in Recurrent and Refractory Hodgkin Lymphoma
Sally Arai,1 Renee Letsinger,1 Ruby M. Wong,2 Laura J. Johnston,1 Ginna G. Laport,1
Robert Lowsky,1 David B. Miklos,1 Judith A. Shizuru,1 Wen-Kai Weng,1 Philip W. Lavori,2
Karl G. Blume,1 Robert S. Negrin,1 Sandra J. Horning3Autologous hematopoietic cell transplantationwith augmented BCNU regimens is effective treatment for re-
current or refractory Hodgkin lymphoma (HL); however, BCNU-related toxicity and disease recurrence re-
main challenges. We designed a conditioning regimen with gemcitabine in combination with vinorelbine in an
effort to reduce the BCNU dose and toxicity without compromising efficacy. In this phase I/II dose escalation
study, the gemcitabine maximum tolerated dose (MTD) was determined at 1250 mg/m2, and a total of 92 pa-
tients were treated at this dose to establish safety and efficacy. The primary endpoint was the incidence of
BCNU-related toxicity. Secondary endpoints included 2-year freedom fromprogression (FFP), event-free sur-
vival (EFS), and overall survival (OS). Sixty-eight patients (74%) had 1 or more previously defined adverse risk
factors for transplant (stage IVat relapse, B symptoms at relapse, greater thanminimal disease pretransplant).
The incidence of BCNU-related toxicity was 15% (95% confidence interval, 9%-24%). Only 2% of patients had
a documented reduction in diffusing capacity of 20%or greater.With amedian follow-upof 29months, the FFP
at 2 years was 71% and theOS at 2 years was 83%. Two-year FFPwas 96%, 72%, 67%, and 14% for patients with
0 (n 5 24), 1 (n 5 37), 2 (n 5 23), or 3 (n 5 8) risk factors, respectively. Regression analysis identified PET
status pretransplant and B symptoms at relapse as significant prognostic factors for FFP. This new transplant
regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-
modeled comparison of this new combination with other conditioning regimens is warranted.
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High-dose chemotherapy and autologous hemato-
poietic cell transplantation (AHCT) is an effective
treatment for patients with recurrent Hodgkin lym-
phoma (HL). Randomized controlled trials have
shown improved freedom from progression (FFP)
with high-dose BEAM (carmustine 300mg/m2, etopo-1Department of Medicine, Blood and Marrow Transplan-
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6/j.bbmt.2010.02.022side, cytarabine, and melphalan) and AHCT over
conventional salvage chemotherapy in chemosensitive
patients [1,2]. The German Hodgkin Lymphoma
Study Group/European Bone Marrow Transplant
Registry (GHSG/EBMT) randomized trial of
BEAM-AHCT versus Dexa-BEAM showed a 3-year
FFP of 55% versus 34%, respectively [2]. Attempts
to improve on FFP in AHCT have included further in-
tensification of salvage therapy before transplant [2-7],
or intensification of the transplant conditioning
regimen itself either with high-dose sequential therapy
[8,9] or with augmented carmustine (BCNU)-based
regimens [10-16]. With increasing doses of BCNU
from 300 mg/m2 to 600 mg/m2, however, the
incidence of pulmonary toxicity increases to 35%
and higher [17-20]. When oral lomustine (CCNU)
was substituted for BCNU in the conditioning, the
interstitial pneumonitis incidence was as high as 63%
[19]. Further, BCNU toxicity is likely underreported
because symptoms of fever, fatigue, nausea, poor1145
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Although it typically responds rapidly to corticosteroid
therapy, the dose-related BCNU syndrome can be po-
tentially life-threatening [22-24]. The high-dose
BCNU regimen most commonly reported in the liter-
ature is CBV (cyclophosphamide [Cy], carmustine 300
mg/m2, and etoposide) [25]. As previously reported by
the Stanford group [12], our variation of the CBV reg-
imen, which utilized high-dose BCNU at a maximum
of 550 mg/m2, was associated with early (within 100
days posttransplant) and late (approximately 6 months
posttransplant) treatment-related deaths, primarily
respiratory (4% early respiratory deaths and 7% late
respiratory deaths).
Gemcitabine and vinorelbine are active drugs in
patients with HL with mechanisms of action distinct
from alkylating agents [26-32]. We hypothesized that
these drugs would allow for reduction of the BCNU
dose in conditioning, thereby reducing early and late
adverse effects of this agent. The combination of
gemcitabine and vinorelbine on days 1 and 8 was
taken from solid tumor experience [33-38]. In this
phase I/II study our goals were to reduce the BCNU
dose from 550 mg/m2 to 350 mg/m2 in an effort to
reduce the risk of pulmonary toxicity while
simultaneously adding gemcitabine and vinorelbine
in an effort to maintain or improve efficacy. We
report the phase I/II experience of utilizing this 5-
drug regimen for the treatment of 92 patients with
relapsed or refractory HL.PATIENTS AND METHODS
Patient Selection
Eligibility criteria included histologically proven,
recurrent or refractory HL confirmed at Stanford
University; aged #70 years; ECOG performance
status 0-2. Adverse risk factors have been previously
defined [12] as: (1) stage IV disease at relapse, (2) con-
stitutional ‘‘B’’ symptoms at relapse, and (3) failure to
achieve minimal disease (single lymph nodes #2 cm
or .75% reduction in a bulky tumor mass or bone
marrow [BM] involvement #10%) at transplant.
High-risk HL patients were defined as those who
had 1 or more of the above risk factors. All patients
signed informed consent for the study approved by
the institutional review board at Stanford University
School of Medicine. Pretransplant testing included
routine staging with medical history, physical exami-
nation, computed tomography (CT) with or without
positron emission tomography (PET), BM aspiration,
and biopsy with cytogenetics, baseline assessment of
cardiac ejection fraction, and pulmonary function tests
(PFTs). Patients with ejection fraction \40% and
diffusion capacity corrected for hemoglobin \55%
were not eligible for the study.The first 7 patients all had high risk features and
were enrolled in the phase I dose escalation study to
determine the maximum tolerated dose (MTD) of
gemcitabine. In phase II, all risk category patients
were accepted.
Study Design
In phase I, gemcitabine was dose-escalated at
planned doses of 1250 mg/m2, 1500 mg/m2, and
1800 mg/m2, in combination with vinorelbine 30
mg/m2 on days 213 and 28, followed by a lowered
dose of BCNU (10 mg/kg and capped at 350 mg/m2,
compared to our standard dose of 15 mg/kg, capped
at 550 mg/m2) on day 26, etoposide 60 mg/kg on
day 24, and Cy 100 mg/kg on day 22. Cohorts of 3
high-risk patients proceeded at each gemcitabine
dose level. Any grade III or IV nonhematologic toxic-
ity constituted an adverse event.
The phase II portion of the study enrolled addi-
tional patients at the gemcitabine MTD.
Autologous Hematopoietic Cell
Transplantation
Patients’ peripheral blood hematopoietic cells
(PBHC) were mobilized from their salvage chemo-
therapy, or from cyclophosphamide 4 g/m2 with
granulocyte-colony stimulating factor (G-CSF) (10
mg/kg per day), or from G-CSF alone per the treating
physician’s discretion. No specific recommendation
was given for salvage chemotherapy prior to AHCT;
however, 40 patients received DHAP (dexamethasone,
cytarabine, cisplatin) [3], 35 patients received ICE
(ifosfamide, carboplatin, etoposide) [5], and 17 pa-
tients received other chemotherapy combinations,
including 2 with a gemcitabine combination. Leuka-
phereses were performed until $2  106 CD34 cells/
kg were collected. The apheresis product was cryopre-
served per institutional practice and infused on
transplant day 0.
Supportive Care
Patients received prophylactic antimicrobial treat-
ment including ciprofloxacin, fluconazole, acyclovir,
and trimethoprim-sulfamethoxazole. Low-dose intra-
venous heparin (100 U/kg/day) as a continuous infu-
sion was used for prevention of sinusoidal
obstruction syndrome (SOS), formerly referred to as
hepatic veno-occlusive disease [39]. Patients received
G-CSF beginning on day 16 after AHCT.
BCNU Toxicity
Clinically significant BCNU-related toxicity was
defined as a noninfectious syndrome of 1 or more of
the following: low-grade fever, dyspnea, fatigue, nau-
sea, poor appetite, weight loss, dry cough, pulmonary
infiltrates, or a decrease in diffusing capacity of up to
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ment of the treating physician, required corticosteroid
therapy in the first 100 days posttransplant. The
BCNU toxicity syndrome was assessed in all patients
and categorized as either predominantly pulmonary
or gastrointestinal (nausea, poor appetite, and weight
loss) [21], based upon symptoms. Pulmonary function
testing was repeated whenever possible for symptom-
atic patients suspected of having the BCNU toxicity
syndrome.
Response Evaluation
The disease status of all patients was evaluated
prior to transplantation utilizing CT or PET-CT im-
aging and BM exam. Posttransplant restaging with CT
or PET-CT imaging was performed routinely at 3
months, 6 months, 1 year, 18 months, 2 years, and an-
nually thereafter until year 5 after transplantation. A
BM biopsy was performed once at 3 months posttrans-
plant and thereafter as clinically indicated. Response to
therapy was assessed according to the revised response
criteria for malignant lymphomas [40]. PET response
followed the guidelines put forth by Hutchings et al.
[41] and Gallamini et al. [42], which categorized pa-
tients as positive, negative, or minimal residual uptake
(MRU, defined as standardized uptake value of 2.0 to
3.5). Patients with PET results showing MRU were
considered PET negative for the purposes of analysis.
Posttransplantation Radiation Therapy
Radiation therapy was administered to selected pa-
tients following transplantation based on previously
published criteria [43]. Posttransplant radiation ther-
apy was typically administered 2-3 months after trans-
plantation.
Statistical Analysis
The goal of the phase I portion of the study was to
define the regimen-related toxicity and to determine
the MTD for gemcitabine. The primary endpoint for
the phase II portion of the study was the incidence of
BCNU-related toxicity. Secondary endpoints in-
cluded 2-year FFP, event-free survival (EFS), and
overall survival (OS) at the gemcitabine MTD. Proba-
bilities of FFP, EFS, and OS over time were estimated
with the product-limit method of Kaplan and Meier
[44]. Progression of HL was the only event defined
in FFP, with censoring at time of nonrelapse death.
Disease progression and death from any cause defined
events in the calculation of EFS. All calculations were
made from the date of transplantation.
The Fisher’s exact test or Pearson chi-square test
was used to examine correlations across prognostic fac-
tors. Cox regression was used in both univariate and
multivariate analyses for each of the outcome
variables (FFP, EFS, and OS). The Wald test wasused in testing hypotheses on covariates. Results from
correlation and univariate analyses guided the selection
of variables in the multivariate stepwise regression
analyses.The log rank testwas used to compare survival
curves.RESULTS
Patient Characteristics
From September 2001 to March 2008, 114 pa-
tients were prospectively screened for enrollment on
the trial at Stanford University Medical Center. Eigh-
teen patients were deemed ineligible because of diffu-
sion capacity for carbon monoxide (DLCO) corrected
for hemoglobin\55% (2 patients), history of recent
pulmonary embolus or radiation pneumonitis (2 pa-
tients), active uncontrolled infection (2 patients),
known allergy to etoposide (1 patient), a history of
grade 3 hemorrhagic cystitis with Cy (1 patient), equal
to or greater than grade 2 sensory or motor peripheral
neuropathy from prior vinca alkaloid (2 patients), prior
malignancy (3 patients), and inadequate PBHC collec-
tion (5 patients).
In phase I, 3 patients received gemcitabine at 1250
mg/m2 without dose-limiting toxicity. Four patients
proceeded to gemcitabine 1500 mg/m2, where the
dose-limiting toxicity was reached in 3 of the patients
based on grade 3-4 elevated liver transaminases and
a symptom complex of fever, headache, and skin toxic-
ity. These 4 patients treated at gemcitabine 1500 mg/
m2 were excluded from phase II analysis. A total of 92
patients were treated at the gemcitabineMTD of 1250
mg/m2, including the first 3 patients in phase I and an
additional 89 patients in phase II, to determine the
safety and efficacy for the phase II analysis.
The pretransplant characteristics for the 92 pa-
tients are shown in Table 1.
Thirty-six patients (39%) were characterized as
primary induction failures. Primary induction failure
was defined as progression of disease during induction
treatment, or initiation of second-line treatment, or re-
sponse of \60 days duration [35]. Fifty-six patients
(61%) had previously achieved a CR (duration .1
year in 22 patients and #1 year in 34 patients). Before
transplantation, most patients received cytoreductive
chemotherapy with the goal of achieving a minimal
disease state. Typical cytoreduction consisted of 2 to
3 cycles of combination chemotherapy.
Status at transplant referred to the response to cy-
toreductive chemotherapy just prior to transplanta-
tion. Eighty-five patients (92%) responded to
treatment before transplant conditioning. Complete
remission or a minimal disease state was achieved in
53 patients (58%). Only 7 patients had stable or pro-
gressive disease. With regard to the previously defined
3 adverse risk factors for prognosis [12], 24 patients
Table 1. Patient Characteristics
Characteristic Total n 5 92
Median age at transplant in years 33 (range 18-64)
Sex
Male 48
Female 44
Initial remission duration
Induction failure 36
#1 year 34
>1 year 22
Prior RT history
None 46
Single course of RT alone 2
Combined modality 44
No. prior chemotherapy regimens*
One 2
Two 74
Three or more 16
Primary chemotherapy
ABVD 60
Stanford V 32
Status at transplant
Complete remission/minimal
disease
53
Partial remission 32
Stable disease 1
Progressive disease 6
PET status at transplant†
Positive 29
Minimal residual uptake (SUV 2.0-
3.5)
6
Negative 42
Not done 15
Risk factors
Stage IV at relapse 29
B symptoms at relapse 39
>Minimal disease at transplant 39
No. of risk factors at transplant‡
0 24
1 37
2 23
3 8
PET indicates positron emission tomography.
*Includes cytoreduction prior to transplant.
†Based on 77 patients who had PET-CT scans.
‡Risk factors defined as stage IV at relapse, B symptoms at relapse, more
than minimal disease at transplant.
Table 2. Regimen-Related Toxicities
N (%)
Toxicity Grade 3 Grade 4 Grade 5
Fever 58 (63)
Mucositis 63 (68)
Skin rash 22 (24)
Headache 6 (7)
Elevated transaminases 37 (40) 2 (2)
SOS 1 (1)
Cardiac (tamponade) 1 (1)
Infection
Bacterial 8 (9)
Fungal 2 (2) 2 (2)
SOS indicates sinusoidal obstruction syndrome.
Total N5 92 patients.
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risk factors.
PET status at the time of transplantation was re-
corded in 77 patients. Thirty-eight percent (29/77) of
patients were PET positive at time of transplant, 55%
(42/77) were PET negative, and 8% (6/77) had MRU.
Hematopoietic Recovery
The median time to absolute neutrophil count
(ANC) .500/mL was 10 days (range: 8-17). The me-
dian time to untransfused platelet count of 20,000/
mL was 15 days (range: 8-34).
Posttransplantation Involved Field Radiation
Therapy
Twenty-two patients received posttransplantation
involved field radiation. The posttransplant radiation
dose ranged from 1200-3600 cGy, depending on pre-vious radiation treatment and normal tissue tolerance.
Fourteen patients received posttransplant regional ir-
radiation (modified mantle or inverted Y) to a total
dose of 3600 cGy, whereas the remaining 8 patients
had variable doses to a single radiation field.
Toxicity
Three patients (3%) suffered early treatment-
related mortality. The causes of early death were fun-
gal infection in 2 patients (day 112 and day 115) and
severe SOS in 1 patient (day134). Fever andmucositis
were the most common grade 3 toxicities, followed by
transaminase elevations, skin rash, headache, and cul-
ture positive infections. Grade 4 toxicities occurred
in only 2 patients and in both cases were related to el-
evated transaminases. Table 2 lists grade 3-4 toxicities.
BCNU-Related Toxicity
The incidence of BCNU-related toxicity in this
study was 15% (14 of 92 patients, 95% confidence in-
terval (CI) 9% to 24%). Table 3 shows the BCNU tox-
icity characteristics. Only 2 patients had a documented
decrease in DLCO of $20%, although 8 others had 1
ormore respiratory symptoms, of whom 3 did not have
formal pulmonary function testing. All patients recov-
ered from the BCNU-toxicity symptoms with cortico-
steroid therapy, which was administered at an initial
dose of 1 mg/kg/day with a taper of 10 mg per week
as tolerated. BCNU-related toxicity was not more
prevalent in patients with a history of chest irradiation.
There was 1 late pulmonary death (day 1532) from
adult respiratory distress syndrome (ARDS).
Survival Data
The median follow-up of the entire group of 92
patients is 29 months (range: 8-86 months). Figure 1
illustrates the Kaplan-Meier survival curves for the
entire population. FFP at 2 years was 71% (CI 61%-
81%) and EFS at 2 years was 67% (CI 57%-77%).
The actuarial 2-year OS was 83% (CI 75% to 91%).
Table 3. BCNU-Related Syndrome Characteristics
Respiratory Signs/Symptoms Nonrespiratory Signs/Symptoms
SPN % DLCO decline C D X F M GI Day Onset
3992 31 C C 42
3837 27 C C 46
3729 16 C C C 60
3079 8 C C C 71
3880 6 C C C 37
3075 ND C C C 44
3435 19 C C 33
3686 16 C C 51
3482 ND C C 97
3756 ND C C C 56
3615 18 C 52
4023 11 C C 68
3789 9 C C 50
3350 ND C C 44
C indicatres cough; D, dyspnea; X, abnormal CXR; F, fever; M, malaise; GI, nausea; SPN, Stanford patient number; DLCO, diffusing capacity for carbon
monoxide.
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study was 6%. Causes of NRM included candidemia,
pulmonary fusariosis, severe SOS, pulmonary embo-
lus, and ARDS. There were 16 deaths, 11 from relapse
and 5 fromNRM.Twelve patients with relapse are still
alive. Of the 7 patients with advanced disease status at
transplant (1 with stable disease and 6 with progressive
disease) (Table 1), 3 patients relapsed within 4 months
of transplant and subsequently died; 1 patient died
from complications of SOS at 1 month posttransplant
and was too early for disease follow-up, and 3 patients
are alive and in CR at last follow-up.
Figure 2a illustrates the Kaplan-Meier plot of FFP
according to the number of risk factors present. The 2-
year FFPwas 96%, 72%, 67%, and 14% for 0, 1, 2, and
3 risk factors, respectively, P\ .0001.
Because response to induction therapy had been
reported to be significantly correlated with the success
of autologous transplantation in recurrent and refrac-
tory HL by Stanford and other groups [9,12,45], we
examined the 2-year FFP according to duration of
initial chemotherapy remission (duration . or \1
year or induction failure). Primary induction failureFigure 1. Survival curves for the entire group of 92 patients. Freedom
from progression (FFP) at 2 years, 71% (CI 61%-81%). Event-free survival
(EFS) at 2 years, 67% (CI 57%-77%). Overall survival (OS) at 2 years, 83%
(CI 75%-91%). Event-free survival (EFS) at 2 years was 67% (CI 57%-77%),
and freedom from progression (FFP) at 2 years was 71% (CI 61%-81%).(IF) was associated with a significantly worse 2-year
FFP of 48% (CI 30%-66%) compared to initial
remission duration #1 year (90%, CI 79%-100%; P
\ .0001), or .1 year (80%, CI 62%-98%, P 5 .05);
however, there was no significant difference in FFP
outcomes between remission duration #1 year or .1
year (P5 .25). Figure 2b shows FFP significantly infe-
rior for IF patients versus non-IF patients (P5 .0003).
The presence of B symptoms at relapse also signifi-
cantly reduced 2-year FFP (56%, CI 38%-74%) versus
without B symptoms (83%, CI 72%-94%), P 5 .008
(Figure 2c). Pretransplant PET status was available
in 77 of the 92 patients and allowed for further analysis.
As shown in Figure 3a, FFP at 2 years was significantly
lower for PET-positive (47%, CI 24%-70%) versus
MRU or PET-negative (87%, CI 76%-98%) patients,
P\ .0001. A summary of survival statistics is provided
in Table 4.
We next explored the significant factors of PET
status, induction response, induction regimen and
constitutional symptoms in multivariate analysis of
77 study participants. Pretransplant PET-positive sta-
tus and constitutional symptoms were significantly
predictive of FFP (hazard ratios [HRs] of 5.9 and
4.8) and EFS (HRs of 3.3 and 4.3). ABVD primary
therapy was of borderline significance (HR of 2.8).
Table 5 summarizes these data.
As shown in Figure 3b, patients with both risk fac-
tors (PET-positive and symptomatic) had a 14% (CI
0%-38%) 2-year FFP compared to 86% (CI 67%-
100%), 82% (CI 63%-100%), and 91% (CI 79%-
00%) 2-year FFP in those who were PET-positive
and asymptomatic, PET-negative and symptomatic,
or PET-negative and asymptomatic, respectively.DISCUSSION
Although high-dose chemotherapy and AHCT is
themost effective treatment for patients with recurrent
Figure 2. (A) FFP in 92 patients according to number of risk factors.
0 (n 5 24), 1 (n 5 37), 2 (n 5 23), 3 (n 5 8). (B) FFP according to in-
duction failure (IF) versus induction response (non-IF). Induction failure
(n5 36), induction response (n5 56). (C) FFP according to presence of
B symptoms at relapse (n5 39) versus absence of B symptoms at relapse
(n 5 53).
Figure 3. (A) FFP in 77 patients according to pretransplant PET status.
PET negative (n5 48), PET positive (n5 29). (B) FFP in patients who are
PET positive, symptomatic (n 5 15), PET positive, asymptomatic
(n5 14), PET negative, symptomatic (n5 19), and PET negative, asymp-
tomatic (n 5 29). Three degrees of freedom log rank test for equality
over 4 groups, P \ .0001. Pairwise significant differences: between
PET1 Bsx1 and PET1Bsx2, P 5 .004; between PET1Bsx1 and
PET2Bsx1, P\.0001; between PET1Bsx1 and PET2Bsx2, P\.0001.
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patients requires new approaches [1,2,9,46,47]. We
sought to reduce the toxicity of the conditioning
regimen while maintaining efficacy to create an
optimal platform for posttransplant therapeutics. In
our previous experience, the pulmonary toxicity
associated with augmented BCNU regimens (550
mg/m2) prohibited the introduction of posttransplant
therapy in the first 100 days [12,19].
The present study was designed to evaluate the fea-
sibility of a transplant regimen in which the combina-
tion of gemcitabine and vinorelbine allowed for
a lowered dose of BCNU along with standard doses
of etoposide and Cy (GN-BVC). It was recognized
that pretransplant GN-containing salvage regimens
were being developed during this trial period with sim-ilar GN-dosing [7]. Our toxicities and responses as
a transplant regimen, compared to a pretransplant sal-
vage approach with GN, however, might be expected
to be different because of the administration close to
BVC and thus, was a new experience.
The primary endpoint of the study was met in
terms of demonstrating a reduced incidence of
BCNU-related toxicity of 15% (CI 9%-24%). A nom-
inal rate of 35% was used as the historic control rate in
the study design, which was a best estimate based on
our own data and those of other studies using aug-
mented BCNU dosing [10-13], and served to
establish the study size for high probability to detect
a toxicity reduction. It should be noted that a more
stringent pulmonary definition of BCNU-related tox-
icity (DLCO decrease $20%) was applied in prior
Stanford studies [19]. In fact, only 2 patients had
a documented DLCO decrease of at least 20% in the
current study, suggesting an even more favorable re-
sult. Reducing the dose of BCNU from 15 mg/kg to
10 mg/kg in this regimen likely contributed to the re-
duced toxicity. Better supportive care in the current
era of autografting [23,48,49], as well as earlier
recognition and initiation of corticosteroid treatment
for BCNU pneumonitis, has undoubtedly played
a role in reducing BCNU-related toxicity and deaths.
Table 4. Summary of Survival Statistics
Variable N 2-Year FFP (%) (95% CI) P* 2-year EFS (%) (95% CI) P* 2-Year OS (%) (95% CI) P*
Overall 92 71 (61-81) 67 (57-77) 83 (75-91)
Risk factors <.0001 .0004 .07
0 24 96 (88-100) 83 (64-100) 80 (58-100)
1 37 72 (56-88) 68 (52-84) 86 (74-98)
2 23 67 (46-88) 67 (46-88) 91 (79-100)
3 8 14 (0-40) 13 (0-36) 42 (1-83)
PET status† <.0001 .003 .07
Negative 48 87 (76-98) 79 (67-91) 91 (82-100)
Positive 29 47 (24-70) 45 (22-68) 77 (58-96)
Initial remission duration .0003 .0002 .025
Non-IF 56 86 (76-96) 82 (71-93) 89 (79-99)
IF 36 48 (30-66) 44 (26-62) 74 (59-89)
B symptoms .008 .005 .18
Absent 53 83 (72-94) 79 (67-91) 85 (73-97)
Present 39 56 (38-74) 52 (36-68) 79 (65-93)
FFP indicates freedom from progression; CI, confidence interval; EFS, event-free survival; OS, overall survival.
*All P values are from the log rank test; 1 degree of freedom for variables with 2 groups; 3 degrees of freedom for number of risk factors.
†N 5 77, as only 77 of the 92 patients had pretransplant PETexams.
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roids in the high dose BCNU regimens; however,
this practice has allowed certain groups to decrease
their incidence of interstitial pneumonitis while main-
taining BCNU doses of 600 mg/m2 [23,49]. A specific
pretransplant pulmonary function threshold that
predicts for posttransplant pulmonary complications
and mortality is not yet established [50], and this
remains the case for BCNU toxicity. A corrected
DLCO of 55% was used for entry onto the current
study, which is the lowest threshold for our institu-
tion’s AHCT regimens, and thus allowed more com-
promised patients to move forward to AHCT with
less toxicity result.
The antitumor efficacy of the conditioning regi-
men did not appear to be compromised in our cohort.
With a median follow-up of 29 months, the 2-year
FFP was 96%, 72%, 67%, and 14% for 0, 1, 2, and 3
risk factors, respectively. As a comparison, in our pre-
vious report [12], the 3-year FFP were 85%, 57%,
41%, and\20% for 0, 1, 2, and 3 risk factors, respec-
tively. Patients with 1 or 2 risk factors appear to benefit
with this new regimen over our historic experience.Table 5. Factors Significantly Affecting FFP and EFS on Multivaria
FFP
Prognostic Factor N* Hazard Ratio (95% CI)
PET status
Negative 1.0
Positive 5.9 (2.0-17.1)
Constitutional B symptoms
Absent 1.0
Present 4.8 (1.5-14.6)
Primary therapy
Stanford V —
ABVD
FFP indicates freedom from progression; PET, positron emission tomography
*N 5 77.The distribution of risk factors was similar in the ear-
lier and current studies [12]. When looking at more
universal risk factor groups, such as duration of first re-
mission, our study results showed 2-year FFP of 48%
for primary IF, 90% for remission duration #1 year,
and 80% for remission duration.1 year. As a compar-
ison, the conditioning approach utilizing high-dose se-
quential therapy followed by BEAM-AHCT, reported
in the phase 2 Cologne trial by the GHSG [8], shows
a freedom from second failure for risk groups having
progressive disease versus early relapse (#1 year) ver-
sus late relapse (.1 year) of 41%, 62%, and 65%, re-
spectively, at a median follow-up of 30 months. The
ongoing GHSG/EBMT randomized trial [9] is inves-
tigating the efficacy of high-dose sequential therapy
and BEAM-AHCT with standard DHAP followed
by BEAM-AHCT, and results are awaited; however,
this is limited to chemosensitive patients and questions
remain on outcomes for chemorefractory patients
prior to AHCT.
Subsequently, FDG-PET imaging has become in-
corporated in HL response assessment [40-42]. In the
current study, pretransplant PET status significantlyte Analysis
EFS
P Hazard Ratio (95% CI) P
.001 .01
1.0
3.3 (1.3-8.0)
.007 .003
1.0
4.3 (1.7-11.2)
.046
— 1.0
2.8 (1.0-7.8)
; CI, confidence interval; EFS, event-free survival.
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and was of borderline significance with regard to OS
(P 5 .07). Constitutional symptoms at relapse (P 5
.008) and induction failure (P 5 .0003) were also
identified as significant adverse risk features. In
multivariate analysis, PET-positive status and consti-
tutional symptoms were independent risk factors for
treatment failure. Further, we observed that the com-
bination of constitutional symptoms and PET-
positive status, representing 19% of patients with
pre-transplant scans, conferred a very poor prognosis,
with just 14% FFP at 2 years. In contrast, FFP at 2
years was .80% for patients with only 1 or neither
risk factor. This observation should be viewed as
hypothesis-generating and interpreted with caution
given the small sample size.
In general, the literature is concordant regarding
adverse risk factors prior to transplant forHL.Constitu-
tional symptoms at relapse, extranodal disease, chemo-
responsiveness before transplantation, and remission
duration\1 year [5,46,51-53] have been reported as
independent predictors of long-term disease-free
survival (DFS) in primary refractory and relapsed HL
patients. More recently, there are several reports indi-
cating theprognostic significanceofPETpretransplant.
The retrospective study by Jabbour et al. [54] identified
pretransplantPETstatus tobe independentlypredictive
for progression-free survival (PFS) and OS. In that
study, 3-year PFS rates for PET positive and negative
patients was 23% and 69%, respectively. Castagna
et al. [55] further showed that early PET after 2 cycles
was predictive of survival after AHCT with 2-year
PFS of 10% for PET-positive versus 93% for
PET-negative patients (P \ .001). Of note, patients
who achieve normalization of PET prior to AHCT
with additional noncross-resistant second-line therapy
had improved EFS in single institution study [56], but
it is unclear if this strategy results in selection bias,
meaningful tumor reduction for cure, or a combination
of both.
In conclusion, the regimen of GN-BVC is associ-
ated with less pulmonary toxicity than the prior aug-
mented BCNU-containing regimen with equal or
greater efficacy. A prospective comparison of this new
combination with other conditioning regimens using
risk stratification is warranted.Whether using the pre-
viously established risk model or incorporating PET,
about two-thirds of patients are alive and event-free
at 2 years after transplant. A small group with multiple
risk factors [12] in our formermodel or both symptom-
atic and PET-positive, had a dismal outcome. Target-
ing these higher risk patients for novel therapies should
be the objective for future studies. TandemAHCT [57]
has been explored in a risk-adapted transplant strategy,
but requires further study. Other approaches could in-
clude antibody-drug conjugates, histone deacetylase
inhibitors, immunomodulating agents, and cell-basedtherapies, which hold promise as peritransplant thera-
peutics [58-61].ACKNOWLEDGMENTS
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